Douglas Pharmaceuticals Europe Limited
Douglas Pharmaceuticals Europe Limited, a prominent player in the pharmaceutical industry, is headquartered in New Zealand (NZ) and operates extensively across Europe. Founded in 1990, the company has established itself as a leader in the development and manufacturing of high-quality generic and branded pharmaceuticals. With a focus on prescription medications, Douglas Pharmaceuticals is renowned for its commitment to innovation and quality, offering a diverse range of products that cater to various therapeutic areas. The company’s unique approach to formulation and production has positioned it favourably within the competitive landscape. Notable achievements include a robust portfolio of products that meet stringent regulatory standards, ensuring safety and efficacy for patients. Douglas Pharmaceuticals continues to expand its market presence, driven by a dedication to improving health outcomes across Europe and beyond.
DitchCarbon Score
How does Douglas Pharmaceuticals Europe Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Retail Trade Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Douglas Pharmaceuticals Europe Limited's score of 31 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Douglas Pharmaceuticals Europe Limited's reported carbon emissions
In 2023, Douglas Pharmaceuticals Europe Limited reported total carbon emissions of approximately 4,805,600 kg CO2e. This figure includes 2,009,020 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 937,960 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. The company has set a significant climate commitment to achieve net zero emissions across all scopes by 2050, with this initiative commencing in 2023. This long-term goal underscores Douglas Pharmaceuticals' dedication to reducing its carbon footprint and addressing climate change effectively. As of now, there is no disclosed data on Scope 3 emissions, which would include indirect emissions from the value chain. However, the company's proactive stance on climate commitments positions it as a responsible player in the pharmaceutical industry, aiming for substantial reductions in its overall environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,009,020 | 0,000,000 |
| Scope 2 | 937,960 | 000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Douglas Pharmaceuticals Europe Limited is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
